Lifecore Biomedical (LFCR) Q2 2025 earnings summary

Executive summary

• Achieved 8% year-over-year revenue growth in Q2 to $32.6M, driven by higher CDMO and HA manufacturing sales, and improved gross margins supported by favorable mix and operational leverage.

• Strengthened balance sheet through $24.3M equity financing, PIPE offering, and favorable restructuring of credit facilities.

• Signed multiple new business development projects, including agreements with Nirsum Laboratories, and expanded the early-stage pipeline to over 50 opportunities, 30% with large pharma.

• Outlined a three-pronged growth strategy targeting 12% revenue CAGR and EBITDA margins over 25% in coming years, with key leadership appointments to support execution.

• Operates as a fully integrated CDMO specializing in sterile injectables and premium HA, serving global biopharma clients.

Financial highlights

• Q2 revenues were $32.6M, up 8% year-over-year; six-month revenues reached $57.3M, up 5%.

• Q2 gross profit was $11.1M (34% margin), up from $10M last year; adjusted EBITDA rose to $6.5M from $5.4M.

• Net loss for Q2 was $6.6M ($0.25/share), compared to net income of $14.2M ($0.39/share) last year, which included a one-time $20.7M non-cash gain.

• Six-month net loss was $22.8M, compared to net income of $3.5M last year, which included a $20.9M non-cash gain.

• Operating loss for the quarter was $2.0M; six-month operating loss was $13.5M.

Outlook and guidance

• FY2025 Adjusted EBITDA guidance is $19M–$21M, compared to $20.2M in FY2024.

• FY2025 net loss expected to be $28.6M–$26.6M, revised due to higher stock-based compensation, interest, and legal costs.

• Revenue guidance for the year remains unchanged at $126.5M–$130M; margins expected in the low 30% range.

• Management expects to complete its multi-year restructuring plan by end of fiscal 2025.

• Believes current cash, operations, and available credit will be sufficient for at least the next twelve months.